Cartesian Growth Corporation II Class A Ordinary Shares (NASDAQ:RENE) — Market Cap & Net Worth
Market Cap & Net Worth: Cartesian Growth Corporation II Class A Ordinary Shares (RENE)
Cartesian Growth Corporation II Class A Ordinary Shares (NASDAQ:RENE) has a market capitalization of $154.70 Million ($154.70 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17605 globally and #4160 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cartesian Growth Corporation II Class A Ordinary Shares's stock price $11.90 by its total outstanding shares 12999700 (13.00 Million). Also see Cartesian Growth Corporation II Class A balance sheet assets for a full breakdown of the balance sheet.
Cartesian Growth Corporation II Class A Ordinary Shares Market Cap History: 2022 to 2025
Cartesian Growth Corporation II Class A Ordinary Shares's market capitalization history from 2022 to 2025. Data shows growth from $133.25 Million to $154.70 Million (6.46% CAGR). Also see Cartesian Growth Corporation II Class A (RENE) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Cartesian Growth Corporation II Class A Ordinary Shares is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1724 of 3165 |
Weight: Cartesian Growth Corporation II Class A Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cartesian Growth Corporation II Class A Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cartesian Growth Corporation II Class A Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check RENE stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RENE by Market Capitalization
Companies near Cartesian Growth Corporation II Class A Ordinary Shares in the global market cap rankings as of September 17, 2026. Review Cartesian Growth Corporation II Class A tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cartesian Growth Corporation II Class A Ordinary Shares by market ranking:
- Twenty One Capital, Inc. (NYSE:XXI): Ranked #6471 globally with a market cap of $1.84 Billion USD.
- Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ:DMII): Ranked #10992 globally with a market cap of $647.19 Million USD.
- Ares Acquisition Corporation II (NYSE:AACT): Ranked #11465 globally with a market cap of $587.05 Million USD.
- Voyager Acquisition Corp (NASDAQ:VACH): Ranked #11869 globally with a market cap of $541.25 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #6471 | Twenty One Capital, Inc. | NYSE:XXI | $1.84 Billion | $5.32 |
| #10992 | Drugs Made In America Acquisition II Corp. Ordinary Shares | NASDAQ:DMII | $647.19 Million | $10.16 |
| #11465 | Ares Acquisition Corporation II | NYSE:AACT | $587.05 Million | $9.49 |
| #11869 | Voyager Acquisition Corp | NASDAQ:VACH | $541.25 Million | $24.79 |
Cartesian Growth Corporation II Class A Ordinary Shares Historical Marketcap From 2022 to 2025
Between 2022 and today, Cartesian Growth Corporation II Class A Ordinary Shares's market cap moved from $133.25 Million to $ 154.70 Million, with a yearly change of 6.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $154.70 Million | +2.06% |
| 2024 | $151.58 Million | +6.58% |
| 2023 | $142.22 Million | +6.73% |
| 2022 | $133.25 Million | -- |
End of Day Market Cap According to Different Sources
On May 12th, 2026 the market cap of Cartesian Growth Corporation II Class A Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $154.70 Million USD |
| MoneyControl | $154.70 Million USD |
| MarketWatch | $154.70 Million USD |
| marketcap.company | $154.70 Million USD |
| Reuters | $154.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cartesian Growth Corporation II Class A Ordinary Shares
Cartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.